P3 Health Partners Inc. Enters Debt Exchange, Issues New Series of Preferred Stock to Regain Nasdaq Compliance

Date: April 28, 2026
Ticker: PIII (Class A Common Stock), PIIIW (Warrants)
Exchange: Nasdaq Stock Market LLC

Key Developments

• Debt Exchange Agreement: P3 Health Partners Inc. (“P3” or the “Company”) and its subsidiary P3 Health Group, LLC (“P3HG”) have entered into a material Debt Exchange Agreement on April 27, 2026. This is a significant strategic move to regain compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of \$2.5 million in stockholders’ equity.
• Issuance of Multiple Series of Cumulative Preferred Stock: As part of this transaction, the Company has authorized and issued four new series of cumulative preferred stock—Series A, B, C, and D—each with different dividend rates and rights.
• Unregistered Sale of Securities: The preferred stock and related securities were sold in a private placement, relying on exemptions from SEC registration requirements. Only accredited investors participated in this offering.
• Amendment to Articles of Incorporation: The Company has amended its charter to facilitate the issuance of these new preferred stock series.

Details of the New Preferred Stock Series

• Series A 13.5% Cumulative Preferred Stock
  • Dividend Rate: 13.5% cumulative, compounding annually, paid on stated value of \$100 per share.
  • Ranking: Senior to all common stock and junior securities with respect to dividends and liquidation.
  • Redemption: Redeemable by the Company at its option with notice (10 to 60 days) and subject to certain subordination obligations.
  • Voting Rights: Limited, but series holders have veto power over actions that adversely affect their rights, such as creating senior stock or amending terms of the series.
  • Not Convertible: No conversion to common stock or other classes.
• Series B 17.5% Cumulative Preferred Stock
  • Dividend Rate: 17.5% cumulative, compounding annually, with option for payment in-kind (PIK) via additional shares.
  • Redemption: Redeemable by the Company or holders (following a Qualified Financing) at \$100 per share plus unpaid dividends.
  • Voting Rights: Robust restrictions—holder consent required for company actions, including creating senior/pari-passu securities, amending terms, or declaring dividends on junior securities.
  • Not Convertible: No conversion into common stock or other classes.
• Series C 19.5% Cumulative Preferred Stock
  • Dividend Rate: 19.5% cumulative, similar payment and compounding terms.
  • Redemption: Similar to Series B; certain liquidity events trigger redemption rights.
  • Voting Rights: Stringent—holder approval required for adverse changes, new senior/pari stock, and other major actions.
  • Not Convertible: No conversion feature.
• Series D 19.5% Cumulative Preferred Stock
  • Dividend Rate: 19.5% cumulative, with similar terms as Series C.
  • Redemption: Redeemable under similar conditions as Series B and C.
  • Voting Rights: Substantially similar to Series C.
  • Not Convertible: No conversion feature.

Other Significant Terms and Shareholder Considerations

• Ranking and Priority: All the new preferred stock series rank senior to common stock in dividends and liquidation. They do not have conversion or preemptive rights. They are not listed or registered for public trading.
• Restrictions on Company Actions: For as long as certain affiliated investors (including Chicago Pacific Founders and its affiliates, the “CPF Parties”) own at least 40% of the Company’s outstanding common stock, they retain substantial information rights, protective provisions, and a standstill agreement that restricts their ownership to 49.99% until at least January 1, 2027.
• Board Oversight: Transactions with CPF affiliates were negotiated and approved by a special committee of independent directors due to their related party nature.
• Potential for Share Price Impact: The transactions are aimed at regaining Nasdaq compliance, improving shareholder equity, and providing financial flexibility. However, the high dividend rates and restrictive preferred stock terms may impact future common stockholder returns and could be viewed cautiously by the market.
• Registration and Transfer Restrictions: All new preferred shares are unregistered and are subject to transfer restrictions. Only accredited investors participated, and resale is subject to further registration or exemption.
• Exhibits and Additional Documents: The Company has filed forms detailing the terms of the preferred stock, the amended charter, and related agreements, all of which are available for review.

Why This Matters for Investors and Shareholders

• Regaining Nasdaq Compliance: The Company faced potential delisting risk due to insufficient equity; this transaction is a direct response to that threat and could stabilize or boost market confidence.
• Dilution and Control: While the new preferred stock is not convertible, it has strong protective provisions, high dividend costs, and significant veto rights over company actions, which could limit strategic flexibility and affect common shareholders’ residual value.
• Financial Flexibility vs. Financial Cost: The high cumulative dividend rates (up to 19.5%) represent a significant ongoing obligation, which may affect future earnings available to common shareholders and the Company’s financial position.
• Private Placement, Not Public Offering: The sale of securities was unregistered and limited to accredited investors, meaning there is no immediate dilution to public common shareholders, but the new preferred equity acts as a senior claim on assets and earnings.
• Potential for Future Corporate Actions: The restrictions imposed by the preferred holders may affect the Company’s ability to raise further capital, issue additional equity, or undertake certain strategic transactions without their consent.
• Related Party Transactions: The involvement of CPF Parties, who are major shareholders and affiliates, may attract regulatory and governance scrutiny, but the use of a special committee may mitigate some concerns.

Conclusion

P3 Health Partners Inc. has taken substantial action to address compliance issues with the Nasdaq Stock Market by entering a Debt Exchange Agreement and issuing high-yield cumulative preferred stock in a private placement. These actions restore compliance, enhance equity, and provide a lifeline for the Company to remain listed. However, the significant rights granted to preferred holders and the high dividend costs are important factors that can materially impact the value and prospects of the Company’s common stock. This is a material and potentially price-sensitive development for investors.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the original filings and consult with their own advisors before making investment decisions. The information is based on filings as of April 28, 2026, and may not include all future developments.

View P3 Health Partners Inc. Historical chart here